Clinical Trials Directory

Trials / Completed

CompletedNCT04508205

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness and Bumps and Blemishes

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
27 (actual)
Sponsor
CAGE Bio Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Open-label multicenter study using CGB-400 Gel to reduce facial redness, bumps, and blemishes.

Detailed description

This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce facial redness and bumps/blemishes typically associated with rosacea. Approximately 25 subjects will be enrolled. Subjects will receive study treatment for 12 weeks and attend a total of 5 study visits (i.e., BL, W2, W4, W8, W12).

Conditions

Interventions

TypeNameDescription
DRUGCGB-400BID application

Timeline

Start date
2018-10-26
Primary completion
2019-04-18
Completion
2019-04-18
First posted
2020-08-11
Last updated
2020-08-12

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04508205. Inclusion in this directory is not an endorsement.

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes (NCT04508205) · Clinical Trials Directory